Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, fibrotic lung disease with no clear etiology and few therapeutic options. Growth factors that act as mediators in the development of this disease might be important therapeutic targets. Nintedanib is a triple-tyrosine kinase inhibitor and a potent antagonist of growth factors such as platelet-derived growth factor, vascular endothelial growth factor, and basic fibroblast growth factor, and it is currently evaluated in clinical trials as a potential IPF therapy. Treatment with nintedanib may slow decline in lung function, decrease the frequency of exacerbations, and improve quality of life in subjects with IPF. This observation, together with extensive safety and pharmacokinetic data from studies of nintedanib in malignancy, led the way for the clinical development of this drug in IPF. Observations from clinical trials, together with the preclinical data, suggest that nintedanib may become an important therapeutic option for individuals with IPF. High-dose nintedanib improved the quality of life, slowed the progression of lung fibrosis and the decline of lung function, and reduced the rate of exacerbations in individuals with mild and moderate IPF. This is a short review based on the available data (September 2013) on nintedanib.
RaghuG, CollardHR, EganJJ, MartinezFJ, BehrJ, BrownKK, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med, 2011; 183(6):788–824.
WalterN, CollardHR, KingTEJr. Current perspectives on the treatment of idiopathic pulmonary fibrosis. Proc Am Thorac Society, 2006; 3(4):330–338.
4.
SodeBF, DahlM, NielsenSF, NordestgaardBG. Venous thromboembolism and risk of idiopathic interstitial pneumonia: a nationwide study. Am J Respir Crit Care Med, 2010; 181(10):1085–1092.
5.
DouglasWW, RyuJH, SchroederDR. Idiopathic pulmonary fibrosis: impact of oxygen and colchicine, prednisone, or no therapy on survival. Am J Respir Crit Care Med, 2000; 161(4 Pt 1):1172–1178.
6.
CollardHR, RyuJH, DouglasWW, SchwarzMI, Curran-EverettD, KingTEJr., BrownKK. Combined corticosteroid and cyclophosphamide therapy does not alter survival in idiopathic pulmonary fibrosis. Chest, 2004; 125(6):2169–2174.
7.
KingTEJr., BrownKK, RaghuG, du BoisRM, LynchDA, MartinezF, et al. BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med, 2011; 184(1):92–99.
8.
KingTEJr., AlberaC, BradfordWZ, CostabelU, HormelP, LancasterL, et al. Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial. Lancet, 2009; 374(9685):222–228.
9.
LowerEE, BaughmanRP. The use of low dose methotrexate in refractory sarcoidosis. Am J Med Sci, 1990; 299(3):153–157.
10.
VenutaF, RendinaEA, CiriacoP, De GiacomoT, PompeoE, BachetoniA, RicciC. Efficacy of cyclosporine to reduce steroids in patients with idiopathic pulmonary fibrosis before lung transplantation. J Heart Lung Transplant, 1993; 12(6 Pt 1):909–914.
11.
SelmanM, CarrilloG, SalasJ, PadillaRP, Pérez-ChaviraR, SansoresR, ChapelaR. Colchicine, D-penicillamine, and prednisone in the treatment of idiopathic pulmonary fibrosis: a controlled clinical trial. Chest, 1998; 114(2):507–512.
12.
DanielsCE, LaskyJA, LimperAH, MierasK, GaborE, SchroederDR, Imatinib-IPF Study Investigators. Imatinib treatment for idiopathic pulmonary fibrosis: randomized placebo-controlled trial results. Am J Respir Crit Care Med, 2010; 181(6):604–610.
13.
RaghuG, BrownKK, CostabelU, CottinV, du BoisRM, LaskyJA, et al. Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial. Am J Respir Crit Care Med, 2008; 178(9):948–955.
14.
BehrJ, DegenkolbB, KrombachF, VogelmeierC. Intracellular glutathione and bronchoalveolar cells in fibrosing alveolitis: effects of N-acetylcysteine. Eur Respir J, 2002; 19(5):906–911.
DroogendijkHJ, Kluin-NelemansHJ, van DoormaalJJ, OranjeAP, van de LoosdrechtAA, van DaelePL. Imatinib mesylate in the treatment of systemic mastocytosis: a phase II trial. Cancer, 2006; 107(2):345–351.
19.
FauselC. Targeted chronic myeloid leukemia therapy: seeking a cure. Am J Health Syst Pharm, 2007; 64(24 Suppl 15):S9–S15.
20.
GoldmanJM, MeloJV. Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med, 2001; 344(14):1084–1086.
21.
StegmeierF, WarmuthM, SellersWR, DorschM. Targeted cancer therapies in the twenty-first century: lessons from imatinib. Clin Pharmacol Ther, 2010; 87(5):543–552.
22.
MaherTM. Pirfenidone in idiopathic pulmonary fibrosis. Drugs Today, 2010; 46(7):473–482.
23.
SpagnoloP, Del GiovaneC, LuppiF, CerriS, BalduzziS, WaltersEH, et al. Non-steroid agents for idiopathic pulmonary fibrosis. Cochrane Database Syst Rev, 2010;(9):CD003134.
24.
BourosD. Pirfenidone for idiopathic pulmonary fibrosis. Lancet, 2011; 377(9779):1727–1729.
25.
TaniguchiH, EbinaM, KondohY, OguraT, AzumaA, SugaM, et al. Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J, 2010; 35(4):821–829.
26.
RothGJ, HeckelA, ColbatzkyF, HandschuhS, KleyJ, Lehmann-LintzT, et al. Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120). J Med Chem, 2009; 52(14):4466–4480.
27.
HilbergF, RothGJ, KrssakM, KautschitschS, SommergruberW, Tontsch-GruntU, et al. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res, 2008; 68(12):4774–4782.
28.
ChaudharyNI, RothGJ, HilbergF, Müller-QuernheimJ, PrasseA, ZisselG, et al. Inhibition of PDGF, VEGF and FGF signalling attenuates fibrosis. Eur Respir J, 2007; 29(5):976–985.
29.
KeaneMP, ArenbergDA, LynchJP3rd, WhyteRI, IannettoniMD, BurdickMD, et al. The CXC chemokines, IL-8 and IP-10, regulate angiogenic activity in idiopathic pulmonary fibrosis. J Immunol, 1997; 159(3):1437–1443.
30.
NissenLJ, CaoR, HedlundEM, WangZ, ZhaoX, WetterskogD, et al. Angiogenic factors FGF2 and PDGF-BB synergistically promote murine tumor neovascularization and metastasis. J Clin Invest, 2007; 117(10):2766–2777.
31.
HamadaN, KuwanoK, YamadaM, HagimotoN, HiasaK, EgashiraK, et al. Anti-vascular endothelial growth factor gene therapy attenuates lung injury and fibrosis in mice. J Immunol, 2005; 175(2):1224–1231.
32.
RicheldiL, CostabelU, SelmanM, KimDS, HansellDM, NicholsonAG, et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med, 2011; 365(12):1079–1087.
33.
GüntherA, KorfeiM, MahavadiP, von der BeckD, RuppertC, MarkartP. Unravelling the progressive pathophysiology of idiopathic pulmonary fibrosis. Eur Respir Rev, 2012; 21(124):152–160.
34.
GotinkKJ, VerheulHM. Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?. Angiogenesis, 2010; 13(1):1–14.
35.
InoueY, KingTEJr., BarkerE, DaniloffE, NewmanLS. Basic fibroblast growth factor and its receptors in idiopathic pulmonary fibrosis and lymphangioleiomyomatosis. Am J Respir Crit Care Med, 2002; 166(5):765–773.
36.
Lo ReS, LecocqM, UwambayinemaF, YakoubY, DelosM, DemoulinJB, et al. Platelet-derived growth factor-producing CD4+ Foxp3+ regulatory T lymphocytes promote lung fibrosis. Am J Respir Crit Care Med, 2011; 184(11):1270–1281.
37.
EbinaM, ShimizukawaM, ShibataN, KimuraY, SuzukiT, EndoM, et al. Heterogeneous increase in CD34-positive alveolar capillaries in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med, 2004; 169(11):1203–1208.
38.
RenzoniEA. Neovascularization in idiopathic pulmonary fibrosis: too much or too little?. Am J Respir Crit Care Med, 2004; 169(11):1179–1180.
39.
SimlerNR, BrenchleyPE, HorrocksAW, GreavesSM, HasletonPS, EganJJ. Angiogenic cytokines in patients with idiopathic interstitial pneumonia. Thorax, 2004; 59(7):581–585.
40.
CosgroveGP, BrownKK, SchiemannWP, SerlsAE, ParrJE, GeraciMW, et al. Pigment epithelium-derived factor in idiopathic pulmonary fibrosis: a role in aberrant angiogenesis. Am J Respir Crit Care Med, 2004; 170(3):242–251.
41.
KoyamaS, SatoE, HaniudaM, NumanamiH, NagaiS, IzumiT. Decreased level of vascular endothelial growth factor in bronchoalveolar lavage fluid of normal smokers and patients with pulmonary fibrosis. Am J Respir Crit Care Med, 2002; 166(3):382–385.
42.
MeyerKC, CardoniA, XiangZZ. Vascular endothelial growth factor in bronchoalveolar lavage from normal subjects and patients with diffuse parenchymal lung disease. J Lab Clin Med, 2000; 135(4):332–338.
43.
WoodcockHV, MolyneauxPL, MaherTM. Reducing lung function decline in patients with idiopathic pulmonary fibrosis: potential of nintedanib. Drug Des Devel Ther, 2013; 7:503–510.
44.
StopferP, RathgenK, BischoffD, LüdtkeS, MarzinK, KaiserR, et al. Pharmacokinetics and metabolism of BIBF 1120 after oral dosing to healthy male volunteers. Xenobiotica, 2011; 41(4):297–311.
45.
GoriB, RicciardiS, FulviA, Del SignoreE, de MarinisF. New oral multitargeted antiangiogenics in non-small-cell lung cancer treatment. Future Oncol, 2012; 8(5):559–573.
46.
GoriB, RicciardiS, FulviA, IntagliataS, Del SignoreE, de MarinisF. New antiangiogenics in non-small cell lung cancer treatment: Vargatef (BIBF 1120) and beyond. Ther Clin Risk Manag, 2011; 7:429–440.
47.
LotaHK, WellsAU. The evolving pharmacotherapy of pulmonary fibrosis. Expert Opin Pharmacother, 2013; 14(1):79–89.
BrownKK, RicheldiL, CostabelU, FlahertyKR, KimD, NoblePW, et al. Treatment of IPF with the tyrosine kinase inhibitor BIBF 1120: patient-reported outcomes in the TOMORROW trial. Am J Respir Crit Care Med, 2012; 185(A3634).
50.
Safety and efficacy of BIBF 1120 at high dose in idiopathic pulmonary fibrosis patients. March25, 2014. Identifier NCT01335464. http://clinicaltrials.gov.
51.
AntoniuSA. Nintedanib (BIBF 1120) for IPF: a tomorrow therapy?. Multidiscip Respir Med, 2012; 7(1):41.
52.
DowneyGP. Resolving the scar of pulmonary fibrosis. N Engl J Med, 2011; 365(12):1140–1141.
